Poor achievement of lipid targets after acute coronary syndrome: what can we improve?

Publisher: Australasian Medical Publishing Co Country of Publication: Australia NLM ID: 0400714 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1326-5377 (Electronic) Linking ISSN: 0025729X NLM ISO Abbreviation: Med J Aust Subsets: MEDLINE

Publication: : Pyrmont, NSW : Australasian Medical Publishing Co.
Original Publication: Sydney : Australasian Medical Pub. Co.

Acute Coronary Syndrome*/drug therapy ; Coronary Artery Disease* ; Hydroxymethylglutaryl-CoA Reductase Inhibitors*; Cholesterol, LDL ; Humans ; Risk Factors

Comment on: Med J Aust. 2022 May 16;216(9):463-468. (PMID: 35236004)

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Eng J Med 2017; 376: 1713-1722.
The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188.
Alsadat N, Hyun K, Boroumand F, et al. Achieving lipid targets within 12 months of an acute coronary syndrome: an observational analysis. Med J Aust 2022; 216: 463-468.
Gitt AK, Lautsch D, Ferrières J, et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II. Atherosclerosis 2017; 266: 158-166.
Gupta A, Thompson D, Whitehouse A, et al; ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017; 389: 2473-2481.
Harris DE, Lacey A, Akbari A, et al. Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: a population-level observational cohort study. Eur J Prev Cardiol 2021; 28: 854-861.
Billimek J, Malik S, Sorkin DH, et al. Understanding disparities in lipid management among patients with type 2 diabetes: gender differences in medication nonadherence following treatment intensification. Womens Health Issues 2015; 25: 6-12.
Zhang Y, Cui Y, Shen M, et al; the medical team from Xiangya Hospital to support Hubei, China. Association of diabetes mellitus with disease severity and prognosis in COVID-19: a retrospective cohort study. Diabetes Res Clin Pract 2020; 165: 108227.
Rodriguez F, Olufade TO, Ramey DR, et al. Gender disparities in lipid-lowering therapy in cardiovascular disease: insights from a managed care population. J Womens Health (Larchmt) 2016; 25: 697-706.

Keywords: Acute coronary syndrome; Cholesterol; Coronary artery disease; Lipids; Risk factors

0 (Cholesterol, LDL)
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)

Date Created: 20220419 Date Completed: 20220517 Latest Revision: 20220720

20221213

10.5694/mja2.51507

35437794